Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc. | a15-22861_1ex99d1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 11, 2015
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
|
001-37526 |
|
26-0389433 |
(State or Other Jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 2.02 Results of Operations and Financial Condition
On November 11, 2015, Zynerba Pharmaceuticals, Inc. (the Company) issued a press release regarding its financial results and operational highlights for the three and nine months ended September 30, 2015. A copy of this press release is furnished as Exhibit 99.1 hereto.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
EXHIBIT |
|
DESCRIPTION |
|
|
|
99.1 |
|
Press Release, dated November 11, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ZYNERBA PHARMACEUTICALS, INC. | ||
|
|
| |
Date: November 12, 2015 |
By: |
/s/ Richard A. Baron | |
|
|
Name: |
Richard A. Baron |
|
|
Title: |
Chief Financial Officer and Treasurer |